Work

639. Oncolytic Adenovirus Expressing IFN Alpha Works Synergistically with Chemoradiation

Year: 2016

Type: article

Abstract: Aside from curative resection, there is no curative treatment against pancreatic adenocarcinoma (PDAC) at present. Late diagnosis and high recurrence results in five-year survival of 6%. Notably, Phase II trials based on adjuvant therapy combining systemic IFN Alpha (IFN) and chemoradiation reported 30-50% increase in two-year survival and impressive 35% increase in five-year survival of PDAC patients. Despite promising results, trial drawbacks included high patient dropout due to IFN systemic toxicity and low IFN levels in tumors.

Source: Molecular Therapy

DOI: 10.1016/s1525-0016(16)33447-5

Authors: Amanda O. Salzwedel, Christopher LaRocca, Joohee Han, Julia Davydova, Masato Yamamoto

Institution: University of Minnesota

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500